首页> 外文期刊>American Journal of Clinical Oncology: Cancer Clinical Trials >Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity.
【24h】

Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity.

机译:经导管动脉化疗不完全栓塞后无法切除的肝细胞癌的早期三维共形放疗:对疗效和毒性的前瞻性评估。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: We prospectively evaluated the efficacy and toxicity of early 3-dimensional conformal radiotherapy (3D-CRT) for patients with unresectable hepatocellular carcinoma (HCC) after incomplete transcatheter arterial chemoembolization (TACE). METHODS: Patients with unresectable HCC who failed 1 or 2 courses of TACE were eligible for this study. Three dimensional-CRT was added for HCC with incomplete uptake of iodized oil. Between January 2006 and February 2007, 40 patients (43 lesions) were enrolled. TACE was performed by using Lipiodol and adriamycin, followed by Gelfoam embolization. Two cycles of TACE were performed in 24 patients (60%), whereas 16 patients (40%) underwent one cycle. The median dose of 54 Gy (3 Gy daily) was delivered with 3D-CRT. Tumor response was evaluated by changes in tumor size on serial computed tomography scans and toxicity was evaluated by the Common Terminology Criteria for Adverse Events v3.0. RESULTS: An objective response was achieved in 27 of 43 lesions (62.8%), with a complete response in 9 lesions (20.9%) and partial response in 18 lesions (41.9%). The overall survival rate was 72.0% at 1 year and 45.6% at 2 years. There was no grade 3 or greater acute toxicity. Nine patients (22.5%) showed progression of the disease within the irradiated field during the follow-up and intrahepatic metastases developed in 16 patients (40.0%). CONCLUSION: Early 3D-CRT for HCC unresponsive to 1 or 2 cycles of TACE resulted in a 62.8% tumor response rate and relatively high complete response rates (20.9%) with acceptable toxicity. This study shows that the application of 3D-CRT could be considered for patients with incomplete TACE.
机译:目的:我们前瞻性评估了早期3维保形放射治疗(3D-CRT)对不完全经导管动脉化疗栓塞(TACE)后无法切除的肝细胞癌(HCC)患者的疗效和毒性。方法:不能切除的HCC患者,如果1或2个疗程的TACE失败,则有资格参加本研究。在不完全摄取碘油的情况下,为肝癌添加了三维CRT。在2006年1月至2007年2月之间,共招募了40位患者(43个病灶)。通过使用Lipiodol和阿霉素进行TACE,然后进行Gelfoam栓塞。 24例患者(60%)进行了两个周期的TACE,而一个周期进行了16例(40%)。 3D-CRT递送的中位剂量为54 Gy(每天3 Gy)。通过在连续计算机断层扫描中通过改变肿瘤大小来评估肿瘤反应,并通过不良事件通用术语标准v3.0来评估毒性。结果:43个病变中有27个(62.8%)达到了客观缓解,其中9个病变(20.9%)完全缓解,18个病变(41.9%)完全缓解。 1年总生存率为72.0%,2年总生存率为45.6%。没有3级或更高的急性毒性。随访期间有9例患者(22.5%)表现出疾病进展,16例患者(40.0%)出现了肝内转移。结论:早期3D-CRT用于HCC对1或2个周期的TACE无反应,导致62.8%的肿瘤缓解率和相对较高的完全缓解率(20.9%),且具有可接受的毒性。这项研究表明,对于不完整的TACE患者,可以考虑使用3D-CRT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号